pulmonary embolism

1. Kevin Pham
May 2014

2. Objective
 T o review the management of acute pulmonary
embolism.

3. Case
 A 48-year-old woman is brought to the emergency room
complaining of a sudden onset of dyspnea. She reports she
was standing in the kitchen making dinner, when she
suddenly felt as if she could not get enough air, her heart
started racing, and she became lightheaded and felt as if
she would faint.
 On examination, she is tachypneic with a respiratory rate of
28 breaths per minute, oxygen saturations 84% on room
air, heart rate 124 bpm, and blood pressure 118/89 mm Hg.
She appears uncomfortable, diaphoretic, and frightened.
Her right leg is moderately swollen from mid-thigh to her
feet, and her thigh and calf are mildly tender to palpation.
Her chest x-ray is interpreted as normal.
Access Medicine

4. Case
 The CT and V/Q scan are broken. What is the next
best step?
 A. Treat empirically with anticoagulation if you cannot
obtain a definitive work up for pulmonary embolism
within 4 hours.
 B. Treat empirically with anticoagulation now.
 C. Treat empirically with anticoagulation if you cannot
get a definitive work up for pulmonary embolism within
24 hours.
 D. Do not treat empirically

5. Introduction
 Mortality without treatment: 30%
 Mortality with effective treatment: 3-8%
 Most deaths are due to recurrent pulmonary embolism
(PE) within the first few hours of the initial event.

6. Initial Resuscitation
 Hypoxia: routine management.
 Hypotension: routine management with IVF.
 Be cautious in patients with RV failure.
 Vasopressors: Levophed is usually first line. Others can
be considered depending on clinical scenario.
 Dobutamine can cause hypotension at low doses since
vasodilation>inotropic effects. Consider concurrent use with
Levophed until higher dose of dobutamine is obtained.

7. Empiric Anticoagulation
UpToDate

8. Risk of Bleeding
 Empiric anticoagulation therapy
should be considered on a case-
by-case basis for patient with
moderate or high risk for
bleeding.
 1 risk factor (moderate):3.2
percent risk of bleeding in the
first three months and 1.6 percent
per year thereafter
 2 risk factors (high): 12.8 percent
in the first three months and ≥6.5
percent per year thereafter
Risk Factors for bleeding
Age >65
Previous bleeding
Thrombocytopenia
Antiplatelet therapy
Recent surgery
Frequent falls
Previous stroke
Diabetes
Anemia
Cancer
Renal failure
Liver failure
Alcohol abuse

9. Anticoagulation
 Anticoagulation improves mortality in clinical trials
 Barritt, DW and Jorder, SC. Anticoagulant drugs in the treatment of pulmonary
embolism. A controlled trial. Lancet. 1960;1(7138):1309.
 Initiation of anticoagulation
 LMWH is preferred in hemodynamically stable patient.
 Subcutaneous fondaparinux is next in line.
 UFH is preferred in setting of persistent hypotension,
poor subcutaneous absorption (morbid obesity), mod-
high bleeding risk, possible thrombolysis, and renal
failure (Cr eatinine clearance <30)

10. Anticoagulation
 Long-term therapy
 Warfarin is recommended due to extensive prior clinical
experience.
 Rivaroxaban and other new oral agents can be
considered if warfarin is not an option.
 LMWH is preferred in those with active malignancy.

11. Anticoagulation
 Duration
 1st episode PE with provoked etiologies (immobility,
surgery, trauma, etc): at least 3 months. (Grade 1B)
 1st episode unprovoked with low-mod bleeding risk:
indefinite. (Grade 2B)
 1st episode unprovoked with high bleeding risk: at least 3
months. (Grade 1B)
 Recurrent with low/mod bleeding risk: indefinite.
(Grade 1A/2B respectively)
 Recurrent with high bleeding risk: at least 3 months.
(Grade 2B)

12. IVC Filter
 Indications
 Contraindications to anticoagulation
 Failed anticoagulation
 Developed a complication due to anticoagulation
 Severe cardiopulmonary compromise where the next PE
will be lethal

13. Case
 A 48-year-old woman is brought to the emergency room
complaining of a sudden onset of dyspnea. She reports she
was standing in the kitchen making dinner, when she
suddenly felt as if she could not get enough air, her heart
started racing, and she became lightheaded and felt as if
she would faint.
 On examination, she is tachypneic with a respiratory rate of
28 breaths per minute, oxygen saturations 84% on room
air, heart rate 124 bpm, and blood pressure 118/89 mm Hg.
She appears uncomfortable, diaphoretic, and frightened.
Her right leg is moderately swollen from mid-thigh to her
feet, and her thigh and calf are mildly tender to palpation.
Her chest x-ray is interpreted as normal.
Access Medicine

14. Case
 The CT and V/Q scan are broken. What is the next
best step?
 A. Treat empirically with anticoagulation if you cannot
obtain a definitive work up for pulmonary embolism
within 4 hours.
 B. Treat empirically with anticoagulation now.
 C. Treat empirically with anticoagulation if you cannot
get a definitive work up for pulmonary embolism within
24 hours.
 D. Do not treat empirically

15. Case
 The CT scan was fixed, and CTA chest shows evidence
of pulmonary embolism. What is the best next step?
 A. Start subcutaneous LMWH only
 B. Start warfarin only
 C. Start subcutaneous LMWH and bridge to warfarin
 D. Start parenteral unfractionated heparin
 E. Start rivaroxaban

16. Summary
 Initial resuscitation is key .
 Empiric anticoagulation should be considered when
the diagnosis cannot be a made in a timely manner.
 Anticoagulation should be prompted with appropriate
agent(s).
 IVF filter should be considered when anticoagulation
is not an option.

17. References
 Kearon, C. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and
Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based
Clinical Practice Guidelines.
 Barritt, DW and Jorder, SC. Anticoagulant drugs in the treatment of pulmonary
embolism. A controlled trial. Lancet. 1960;1(7138):1309.
 Tapson, VF. Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower
extremity deep vein thrombosis. UpToDate.
 Tapson, VF. Treatment of acute pulmonary embolism. UpToDate.